China International Capital Corporation and CITIC are co-sponsors of Shulan Medical, China's leading technology healthcare group, which submitted its listing application in Hong Kong, according to HKEx filings on Aug. 28.
It is reported that Shulan Medical is a leading science and technology-based social medical group in China, which integrates health care services, medical scientific research and medical education. As of the date of disclosure of the prospectus, the company has owned and operated three socially run comprehensive medical institutions: Shulan (Hangzhou), Shulan (Anji) and Shulan (Quzhou). Among them, Shulan (Hangzhou) Hospital has established 46 clinical disciplines and 13 medical technology departments, is one of the few socially run medical institutions awarded third-class first-class hospitals, and became an international hospital certified by JCI in 2017.
Shulan Medical has been ploughing the field of difficult and critical diseases for many years and has the comprehensive ability to provide high-quality medical services to patients suffering from difficult and critically ill patients throughout the country. With profound medical expertise, Shulan (Hangzhou) Hospital has become the only social medical institution in China that can carry out liver, kidney, heart and lung transplantation at the same time. According to the total number of patients discharged from Frost Sullivan in 2022, Shulan Medical ranks first among all social medical institutions in Zhejiang Province and third among all social offices and public medical institutions in Zhejiang Province.
According to the prospectus, from 2020 to the end of March 2023, Shulan Medical's operating income was 1.618 billion yuan, 1.548 billion yuan, 1.778 billion yuan and 486 million yuan respectively.